Journal
INFECTIOUS DISEASES AND THERAPY
Volume 11, Issue 1, Pages 217-230Publisher
SPRINGER LONDON LTD
DOI: 10.1007/s40121-021-00557-w
Keywords
Ceftaroline fosamil; Complicated skin and soft tissue infection; Comorbidities
Categories
Funding
- Forest Laboratories - AbbVie
- AstraZeneca
- Pfizer
Ask authors/readers for more resources
This analysis evaluated the impact of underlying comorbidities on clinical outcomes in patients with complicated skin and soft tissue infections (cSSTIs) treated with ceftaroline fosamil compared to vancomycin plus aztreonam. Regardless of age and comorbidities such as diabetes, peripheral vascular disease, and cancer/malignancy, outcomes were similar between the treatment groups. Subgroup analyses showed consistent efficacy and safety results with those of the overall cSSTI population.
Introduction In three phase III randomized controlled trials, ceftaroline fosamil was shown to be non-inferior to vancomycin plus aztreonam for the treatment of complicated skin and soft tissue infections (cSSTIs). This exploratory analysis evaluated the impact of underlying comorbidities on clinical outcomes in patients with cSSTI pooled from these three studies. Methods CANVAS 1 and 2 and COVERS evaluated ceftaroline fosamil (600 mg every 12 h [q12h]; 600 mg every 8 h [q8h; COVERS]) versus vancomycin plus aztreonam (1 g q12h each [CANVAS 1 and 2]; vancomycin 15 mg/kg q12h and aztreonam 1 g q8h [COVERS]) in hospitalized adults with cSSTI. The primary efficacy variable in each trial was clinical response at the test-of-cure (TOC) visit. Subgroup analyses were performed on the pooled clinically evaluable (CE) population, exploring the impact of age and various baseline comorbidities. Results Overall, 1808 patients were included in the CE population (1005 ceftaroline fosamil; 803 vancomycin plus aztreonam). Clinical cure rates at TOC were 89.7% (ceftaroline fosamil) and 90.8% (vancomycin plus aztreonam) (difference [95% confidence interval] - 1.13 [- 3.87, 1.67]). Clinical response rates were similar between treatment groups, regardless of age (<= 65 years or > 65 years), and in subgroups of patients with and without diabetes mellitus, peripheral vascular disease, cancer/malignancy, renal impairment, and obesity; within these subgroups, efficacy and safety results were generally consistent with those of the overall cSSTI population. Conclusions This analysis provides supportive evidence of the efficacy of ceftaroline fosamil in patients with cSSTI and underlying comorbidities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available